True Health, a Guangdong-based surgical robot developer backed by Gree Group, has reportedly raised over RMB 100 million (approximately USD 14 million) in a Series B+ financing round. This significant funding will be allocated to enhance research and development efforts, accelerate innovation in the surgical robot sector, and procure essential core components along with artificial intelligence applications.
Innovative Surgical Solutions and Partnerships
Founded in 2018, True Health has achieved Category III approval for its soft tissue puncture surgery robot in China. The company is recognized for pioneering the “puncture surgery navigation and positioning system,” which has positioned it as a leader in the field. True Health has also established partnerships with several top medical institutions and prestigious universities, particularly focusing on advancing respiratory disease treatments in China.
Future Prospects in Surgical Robotics
With the new funding, True Health aims to solidify its market position and expand its technological capabilities in surgical robotics. The company’s commitment to innovation and collaboration with leading medical entities underscores its potential to significantly impact the healthcare landscape in China.- Flcube.com
